Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Rights Issue Webinar hosted by HC Andersen Capital (March 2023)
11 slides from Expres2ion Biotech Holding Ab's conference presentation, Mar 31, 2023
Slide 1: Proteins for Life
Rights Issue Webinar | March 2023 Proteins for Life A prospectus has been prepared in connection with the Rights Issue, which is referred to in this Presentation, and has been reviewed and approved by the Swedish Financial Supervisory Authority. Such approval shall not be regarded as an approval of
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by ExpreS2ion Biotech Holding AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of
Slide 3: Investment Highlights
Investment Highlights We turn complex proteins into tomorrow’s vaccines High-potential pipeline of key focus within infections diseases and oncology, backed up by strong intellectual property rights. Targeting sizeable unmet medical needs and markets Vaccine development platform with strong track re
Slide 4: ExpreS2ion's Business Model
2 ExpreS ion’s Business Model Deep pipeline for value creation and revenue generating CRO business ExpreS2 Platform for Protein Expression +500 different proteins have been produced with the ExpreS2 platform, while posting a success rate exceeding 90% across +100 clients and partners Novel Pipeline
Slide 5: Unique Technology Platforms
Unique Technology Platforms Combines a highly immunogenic antigen with unique presentation technology Particle (VLP) technology ExpreS2 platform - AdaptVac’s proprietary virus- - Combines S2 cells with like particles (VLP) technology patented expression vectors securely attaches our proteins (add a
Slide 6: Deep Vaccine Pipeline for Value Creation
Deep Vaccine Pipeline for Value Creation Numerous projects across all development stages with additional exploratory focus Development Progress Market Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Potential Pharmacology >€30 billion1 COVID-19 ABN
Slide 7: Summary
Summary Rights issue up to SEK 102.4 million corresponding to 20,892,660 new shares • Subscription and guarantee undertakings of 50.5% of the Rights Issue corresponding to approximately SEK 51.3 million • Subscription price of SEK 4.90 per share • 29 March – 12 April: Unit rights can be subscribed f
Slide 8: Use of Proceeds
Use of Proceeds 2) Internal technology development 1) Advance the breast cancer vaccine 30% candidate ES2B-C001 43% 27% 3) Pipeline expansion Proteins for Life |8
Slide 9: Mechanics
Mechanics Unit subscription period TO 8 warrants subscription period 29 March – 12 April 2023 7 – 21 September 2023 *The subscription price has been set to SEK 4.90 per Unit, which corresponds to SEK 4.90 per share. The warrants of series TO 8 are issued free of charge. **Against a cash payment Prot
Slide 10: Timetable
Timetable Event Timing Last day of trading in shares including right to receive 23 March 2023 unit rights First day of trading in shares excluding right to 24 March 2023 receive unit rights Record date for participation in the Rights Issue 27 March 2023 Prospectus is published 27 March 2023 Subscrip
Slide 11: Proteins for Life
Get the latest investor news: Company announcements: • Open https://expres2ionbio.com/ • Scroll to the bottom of the page • Fill out the required fields • Click “subscribe” Investor newsletter • Open https://news.cision.com/expres2ion-biotechnologies • On that page, click on the envelope to subscrib
ExpreS2ion Biotech Holding — Rights Issue Webinar hosted by HC Andersen Capital (March 2023) on 6ix